HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kita, T. Articles by Ishibashi, T. Search for Related Content PubMed PubMed Citation Articles by Kita, T. Articles by Ishibashi, T. Social Bookmarking                What's this?

Transforming Growth Factor-ß2 and Connective Tissue Growth Factor in Proliferative Vitreoretinal Diseases

Possible Involvement of Hyalocytes and Therapeutic Potential of Rho Kinase Inhibitor

¹ Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
² Department of Cardiology, Graduate School of Medicine, Tohoku University, Miyagi, Japan

Address correspondence and reprint requests to Yasuaki Hata, MD, PhD, Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka 812-8582, Japan. E-mail: hatachan{at}med.kyushu-u.ac.jp

Abbreviations: CTGF, connective tissue growth factor; DMEM, Dulbecco’s modified Eagle’s medium; MAPK, mitogen-activated protein kinase; PDR, proliferative diabetic retinopathy; PVR, proliferative vitreoretinopathy; RRD, rhegmatogenous retinal detachment; TGF-ß, transforming growth factor-ß

The critical association of connective tissue growth factor (CTGF), which is thought to be one of the downstream mediators of transforming growth factor-ß (TGF-ß), with vitreoretinal diseases remains to be clarified. In the current study, we first demonstrated the correlation between the concentrations of TGF-ß2 as well as CTGF in the vitreous and CTGF gene regulation in cultured hyalocytes. Concentrations of TGF-ß2 and CTGF in the vitreous from patients with proliferative vitreoretinal diseases were significantly higher than in those with nonproliferative diseases, and there was a positive correlation between their concentrations (r = 0.320, P < 0.01). Cultured hyalocytes expressed CTGF mRNA, which was enhanced in the presence of TGF-ß2, associated with nuclear accumulation of Smad4. TGF-ß2–dependent Smad4 translocation and CTGF gene expression were mediated through Rho kinase and at least partially via p38 mitogen-activated protein kinase. Finally, fasudil, a Rho kinase inhibitor already in clinical use, inhibited both Smad4 translocation and CTGF gene expression. In conclusion, combined effects of TGF-ß2 and CTGF appear to be involved in the pathogenesis of proliferative vitreoretinal diseases. Hyalocytes may be a possible source of CTGF and thus might play a role in vitreoretinal interface diseases. Furthermore, Rho kinase inhibitors might have therapeutic potential to control fibrotic disorders in the eye.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Kita, Y. Hata, M. Miura, S. Kawahara, S. Nakao, and T. Ishibashi Functional Characteristics of Connective Tissue Growth Factor on Vitreoretinal Cells Diabetes, May 1, 2007; 56(5): 1421 - 1428. [Abstract] [Full Text] [PDF]